Find and Pitch Jounalists, Get Your Story Covered

Tags: biotech patient pharma Policy & Regulation policy-regulation

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	CatalYm shows potential of visugromab for treating cachexia - 19 days ago Arcellx to present positive data on multiple myeloma treatments - about 2 months ago Andrew Caldwell - 9 months ago
2	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - about 1 month ago Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval - about 1 month ago Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer - 2 months ago Amylyx Aims to Help Patients With a Novel GLP-1 Drug, But Not the Way You Think - 6 months ago Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer - 7 months ago Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds - 8 months ago Amylyx Withdraws ALS Drug From Market; Restructuring Will Slash 70% of Staff - 9 months ago
3	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - about 1 month ago
4	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - about 1 month ago Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - 5 months ago Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 7 months ago After Amylyx drug failure, what’s next for ALS? - 10 months ago ‘1 plus 1 equals 3’ — the co-CEO model in pharma - 11 months ago
5	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	A diabetes drug, twice rejected, stumbles again — but its developer persists - about 2 months ago Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 5 months ago
6	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts Biologic License Application for Biosimilar Denosumab - about 2 months ago FDA Approves Oral Sulopenem Etzadroxil and Probenecid for Uncomplicated Urinary Tract Infections - 2 months ago Study: Biosimilarities Found Between Yusimry and Humira for Immune, Rheumatic Conditions - 12 months ago
7	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	Amy Abernethy, former No. 2 at FDA, outlines new company’s plans to streamline clinical research - 2 months ago
8	Natasha Lomas TechCrunch Journalist. Climber-in-training. Owns cats. Barcelona and London journalismclimbing	French cleantech startup Calyxia nets $35M to tackle microplastics pollution - 4 months ago
9	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 4 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 10 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 10 months ago STAT+: In stunning outcome, Amylyx’s ALS drug fails large clinical trial - 10 months ago STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves - 10 months ago STAT+: Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease - 11 months ago
10	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 4 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 10 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 11 months ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - about 1 year ago

Journalists covering Amylyx